title: Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
abstract: BACKGROUND
  Clinical criteria for differentiating Parkinson's disease (PD) with dementia (PDD) from dementia with Lewy bodies (DLB) are unsatisfactory. Their existence as distinct clinicopathologic entities is still debated, although the burden of Alzheimer's disease (AD) pathology seems higher in DLB. Thus, analysis of cerebrospinal fluid (CSF) biomarkers (beta-amyloid(1-42) [Abeta42], total tau, and hyperphosphorylated tau [p-tau]) in living subjects might provide significant pathophysiological information on these diseases.
  
  
  METHODS
  Cerebrospinal fluid biomarkers were measured in DLB (n = 19), PDD (n = 18), and AD (n = 23) subjects matched for age, sex, and dementia severity, as well as in PD (n = 20) and normal control subjects (n = 20).
  
  
  RESULTS
  DLB showed the lowest mean CSF Abeta42 levels, with a negative association to dementia duration (rho = -.42, p = .07). In DLB patients, mean CSF total tau levels were significantly lower than in AD patients (508 +/- 387 vs. 960 +/- 619, respectively) but twofold to threefold higher than in PDD (286 +/- 184), PD (160 +/- 64), or normal control subjects (177 +/- 76), with a positive association to dementia severity (Mini-Mental State Examination: rho = -.54, p = .02; Milan Overall Dementia Assessment: rho = -.66, p = .002). PDD patients had mean CSF Abeta42 and total tau levels similar to those seen in PD patients. Hyperphosphorylated tau was significantly increased in the AD group only.
  
  
  CONCLUSIONS
  Cerebrospinal fluid Abeta42 and total tau have a different behavior in DLB and PDD, being related to duration and severity of dementia in DLB alone. Hyperphosphorylated tau is not significantly altered in these conditions.
authors.affiliation: Section of Neurology, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Perugia General Hospital, Perugia, Italy. parnetti@unipg.it
authors.forename: Lucilla
authors.initials: L
authors.lastname: Parnetti
authors.forename: Pietro
authors.initials: P
authors.lastname: Tiraboschi
authors.forename: Alessia
authors.initials: A
authors.lastname: Lanari
authors.forename: Maria
authors.initials: M
authors.lastname: Peducci
authors.forename: Chiara
authors.initials: C
authors.lastname: Padiglioni
authors.forename: Cataldo
authors.initials: C
authors.lastname: D'Amore
authors.forename: Laura
authors.initials: L
authors.lastname: Pierguidi
authors.forename: Nicola
authors.initials: N
authors.lastname: Tambasco
authors.forename: Aroldo
authors.initials: A
authors.lastname: Rossi
authors.forename: Paolo
authors.initials: P
authors.lastname: Calabresi
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D000704:Analysis of Variance; D015415:Biomarkers / Q000134:cerebrospinal fluid; D016022:Case-Control Studies; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000150:complications; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000134:cerebrospinal fluid* / Q000150:complications; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000150:complications; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins